title: Primary cutaneous posttransplant lymphoproliferative disorders in solid organ transplant recipients: a multicenter European case series.
abstract: Primary cutaneous posttransplant lymphoproliferative disorders (PTLD) are rare. This retrospective, multicenter study of 35 cases aimed to better describe this entity. Cases were (re)-classified according to the WHO-EORTC or the WHO 2008 classifications of lymphomas. Median interval between first transplantation and diagnosis was 85 months. Fifty-seven percent of patients had a kidney transplant. Twenty-four cases (68.6%) were classified as primary cutaneous T cell lymphoma (CTCL) and 11 (31.4%) as primary cutaneous B cell PTLD. Mycosis fungoides (MF) was the most common (50%) CTCL subtype. Ten (90.9%) cutaneous B cell PTLD cases were classified as EBV-associated B cell lymphoproliferations (including one plasmablastic lymphoma and one lymphomatoid granulomatosis) and one as diffuse large B cell lymphoma, other, that was EBV-negative. Sixteen (45.7%) patients died after a median follow-up of 19.5 months (11 [68.8%] with CTCL [6 of whom had CD30(+) lymphoproliferative disorders (LPD)] and 5 [31.2%] with cutaneous B cell PTLD. Median survival times for all patients, CTCL and cutaneous B cell PTLD subgroups were 93, 93, and 112 months, respectively. Survival rates for MF were higher than those for CD30(+) LPD. The spectrum of primary CTCL in organ transplant recipients (OTR) is similar to that in the general population. The prognosis of posttransplant primary cutaneous CD30(+) LPD is worse than posttransplant MF and than its counterpart in the immunocompetent population. EBV-associated cutaneous B cell LPD predominates in OTR.
authors.affiliation: Department of Dermatology, Başkent University Faculty of Medicine, Ankara, Turkey. denizs@baskent-ank.edu.tr
authors.forename: D
authors.initials: D
authors.lastname: Seçkin
authors.forename: S
authors.initials: S
authors.lastname: Barete
authors.forename: S
authors.initials: S
authors.lastname: Euvrard
authors.forename: C
authors.initials: C
authors.lastname: Francès
authors.forename: J
authors.initials: J
authors.lastname: Kanitakis
authors.forename: A
authors.initials: A
authors.lastname: Geusau
authors.forename: V
authors.initials: V
authors.lastname: Del Marmol
authors.forename: C A
authors.initials: CA
authors.lastname: Harwood
authors.forename: C M
authors.initials: CM
authors.lastname: Proby
authors.forename: I
authors.initials: I
authors.lastname: Ali
authors.forename: A T
authors.initials: AT
authors.lastname: Güleç
authors.forename: E
authors.initials: E
authors.lastname: Durukan
authors.forename: C
authors.initials: C
authors.lastname: Lebbé
authors.forename: M
authors.initials: M
authors.lastname: Alaibac
authors.forename: E
authors.initials: E
authors.lastname: Laffitte
authors.forename: S
authors.initials: S
authors.lastname: Cooper
authors.forename: J N
authors.initials: JN
authors.lastname: Bouwes Bavinck
authors.forename: G M
authors.initials: GM
authors.lastname: Murphy
authors.forename: C
authors.initials: C
authors.lastname: Ferrándiz
authors.forename: C
authors.initials: C
authors.lastname: Mørk
authors.forename: P
authors.initials: P
authors.lastname: Cetkovská
authors.forename: W
authors.initials: W
authors.lastname: Kempf
authors.forename: G F L
authors.initials: GF
authors.lastname: Hofbauer
mesh_terms: D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007390:International Agencies; D016410:Lymphoma, T-Cell, Cutaneous / Q000175:diagnosis / Q000209:etiology* / Q000401:mortality; D008232:Lymphoproliferative Disorders / Q000175:diagnosis / Q000209:etiology* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000175:diagnosis / Q000209:etiology* / Q000401:mortality; D016377:Organ Transplantation / Q000009:adverse effects*; D011183:Postoperative Complications; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D012878:Skin Neoplasms / Q000175:diagnosis / Q000209:etiology* / Q000401:mortality; D015996:Survival Rate
keywords: B cell; CD30 positive lymphoma; T cell; immunosuppressant therapy; organ transplantation; posttransplant lymphoma; posttransplant lymphoproliferative disorder; skin cancer